Denali Therapeutics Inc. — Director's Dealing 2017

Dec 8, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2017-12-07

Reporting Person: FLATLEY JAY T (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-07	Stock Option (right to buy)	$18.00	A	47165	Acquired	2027-12-06	Common Stock (47165)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.